ASCO 2025: Focus on Treatment Sequencing in mBC
Dr. Kelly McCann reviews sequencing and emerging therapies in HR-positive, HER2-negative metastatic breast cancer. Dr. Kelly McCann of UCLA details HER2-positive breast cancer sequencing and toxicity management. Dr. Kelly McCann discusses evolving treatment sequencing strategies in metastatic triple-negative breast cancer. Dr. Gradishar discusses how tolerability, toxicity, and NCCN guidelines shape HER2+ breast cancer treatment decisions.
Dr. William Gradishar discusses treatment sequencing strategies for HER2+ metastatic breast cancer at ASCO 2025.